NCI SBIR Webinar: Direct-to-Phase II Pilot and NCI Phase IIB Bridge Award

On Thursday, March 6, the National Cancer Institute Small Business Innovation Research Development Center (NCI SBIR) will provide an exclusive chance to learn more about two new funding opportunities.

  • Direct-to-Phase II Pilot, PAR-14-088: Apply by April 5, 2014
  • FY14 Phase IIB Bridge Award, RFA-CA-14-002: Apply by April 21, 2014

NCI SBIR Webinar on Direct-to-Phase II Pilot Program and
Phase IIB Bridge Award 

March 6, 2014
12:30 – 1:45 p.m. EST
Registration is free but required. Register here.

This is an important event to learn more about opportunities for more advanced stage small businesses in the NCI SBIR & STTR Programs. Hear about:

  • The new Direct-to-Phase II Pilot Program.
  • NCI’s Phase IIB Bridge Award, now with expanded eligibility.
  • Recent policy changes that expand program eligibility to venture capital backed companies, and allow SBIR & STTR switching.
  • Practical strategies and tips for developing competitive proposals, proper stage of development, and other factors that NCI is looking for when reviewing applications.

The Direct-to-Phase II Pilot is a new program to expand opportunities for companies and to accelerate the pace of technology development and commercialization. Applicants that have demonstrated the R&D and technical merit characteristics of a Phase I SBIR project are encouraged to apply.

The Phase IIB Bridge Award is for SBIR & STTR Phase II awardees. This is NCI’s program to bridge the funding gap between the end of the SBIR & STTR Phase II award and subsequent rounds of financing needed to advance a promising product or service toward commercialization. This award is designed to incentivize partnerships between federal SBIR & STTR Phase II awardees and third-party investors or strategic partners.

This webinar session will be led by NCI SBIR Development Center Program Directors Andrew Kurtz and Patti Weber and will highlight initiatives designed to help mid-stage and advanced small businesses transition their promising innovations from the lab to the marketplace.